References
- American Cancer Society. Cancer Facts & Figures 2015. Atlanta, GA: American Cancer Society, 2015. http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf. Accessed April 21, 2015
- National Cancer Institute. Surveillance Epidemiology and End Results Program. 2012. http://seer.cancer.gov/archive/csr/1975_2012/browse_csr.php?sectionSEL=1&pageSEL=sect_01_table.29.html Accessed June 1, 2016
- Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2010. Bethesda, MD: National Cancer Institute, 2013. http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission. Accessed April 21, 2015
- National Cancer Institute. Breast Cancer Treatment Health Professional Version. http://www.cancer.gov/types/breast/hp/breast-treatment-pdq Accessed June 1, 2016
- Blowers E, Foy S. Breast cancer overview: current treatments. Practice Nursing 2009;20:282–6. http://libpublic3.library.isu.edu/login?url=http://search.ebscohost.com/login.aspx?direct=true&db=c8h&AN=2010314794&site=ehost-live. Accessed April 21, 2015
- Ferrario C, Batist G. Advances in the approach to novel drug clinical development for breast cancer. Expert Opin Drug Discov 2014;9:647-68
- Tinoco G, Warsch S, Glück S, et al. Treating breast cancer in the 21st century: emerging biological therapies. J Cancer 2013;4:117-32
- Rashid N, Koh HA, Baca HC, et al. Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system. JMCP 2015;21:863-71
- Hurvitz S, Guerin A, Brammer M, et al. Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting. Oncologist 2014;19:901-8
- Crown J, Diéras V, Kaufmann M, et al. Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol 2002;3:719-27
- Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol 2002;20:4636-42
- Hassett MJ, O’Malley AJ, Pakes JR, et al. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-17
- Goyal RK, Wheeler SB, Kohler RE, et al. Health care utilization from chemotherapy-related adverse events among low-income breast cancer patients: effect of enrollment in a medical home program. N C Med J 2014;75:231-8
- Hansen RN, Ramsey SD, Lalla D, et al. Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens. Springerplus 2014;3:259
- Ray S, Bonthapally V, McMorrow D, et al. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. Comp Eff Res 2013;2:195-206
- Hao Y, Meyer N, Song X, et al. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics. Curr Med Res Opin 2015;31:275-88
- Donato BM, Willey BL, Cohenuram M, et al. Treatment patterns in patients with advanced breast cancer who were exposed to an anthracycline, a taxane and capecitabine: a descriptive report. Clin Ther 2010;32:546-54
- Bradly CJ, Gardiner J, Given CW, et al. Cancer, Medicaid enrollment and survival disparities. Cancer 2005;103:1712-18
- National Cancer Institute. SEER-Medicare Calculation of Comorbidity Weights. March 2015. http://healthcaredelivery.cancer.gov/seermedicare/program/comorbidity.html Accessed June 1, 2016
- Lyman GH, Berndt ER, Kallich JD, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-56
- Burke TA, Wisniewski T, Ernst FR. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 2011;19:131-40
- Liou SY, Stephens JM, Carpiuc KT, et al. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Invest 2007;27:381-96